Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...

Conducted by Emory University and Grady Health System and funded by Gilead, the trial showed that Lenacapavir offers a ...

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

A new, long-acting injectable to prevent HIV infection could be a “game-changer” in ending the AIDS epidemic, if all who ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...